Genmab — Januar 2019
-
Den gode skribent efterlyste jo organisationsændringer fra min hånd
-
vi kan ikke helt være med der Nohope, vores lidt over 5k aktier per mand gør sgu ikke den store forskel
-
ja, jeg mente det nok.Vi har tabt en ferrari og en lamborghini per mand siden 18 okt 2017
-
du har/havde også Pandora ikke?
-
geez
-
det er noget af en syg kombi
-
-
Godmorgen. Uha.det er grimt at sidde på toppen af sådan en udvikling. Jeg har desværre også prøvet det
-
can't see anything new really in the Novartis report, confirmation that - the Phase III program for
OMB157 in relapsing MS
is fully enrolled and is on track for completion in 2019.
In addition, a registration study for Japan was initiated
in March 2018.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind